This profile describes access and programme structure. Inclusion is not an endorsement, regulatory finding, or clinical recommendation. Prescription decisions belong to a qualified prescriber.
At a glance
Pricing, medicine, location, care, fulfilment, funding, and policy claims are separated below.
An open check means the public sources were not specific enough—not that the service failed the check.
Resumen en español
LifeMD para usuarios hispanohablantes
Esta sección ofrece una orientación breve en español sobre el perfil estadounidense. La investigación completa de precios, acceso, farmacia y seguimiento permanece arriba mientras ampliamos la revisión editorial en español.
No encontramos una fuente primaria suficientemente específica para afirmar que una cita clínica esté disponible en español. Confirma el idioma y cualquier servicio de interpretación antes de pagar.
- si la cita concreta será en español;
- el coste mensual ordinario y qué incluye;
- la licencia estatal del profesional;
- el medicamento, la farmacia y el coste por separado.
Esta traducción editorial no demuestra que el proveedor ofrezca atención clínica en español y no sustituye una valoración médica.
Comparar proveedores para hispanohablantes en EE. UU. →How the program is structured
A clinician-led membership that separates the care program from medication cost, supports insurance authorization, and includes coaching and essential lab work under stated conditions.
GLP.directory checked the cited public sources on Sep 13, 2026. We reviewed published access, cost, care, fulfilment, funding, cancellation, monitoring, and switching details; we have not audited individual clinical encounters, prescriptions, pharmacy operations, or outcomes.
Availability can change by state, clinician, medical history, product, pharmacy, inventory, and insurance plan. “Not publicly confirmed” means we did not find a sufficiently specific answer in the cited public material. Confirm the current patient-specific answer before paying or changing care.
Service configuration
These structured fields power the directory filters. They describe the reviewed public route and should be reconfirmed for the selected plan.
- Provider type
- Telehealth program
- Medicine context
- Semaglutide (Wegovy; Ozempic/Rybelsus for type 2 diabetes) · Tirzepatide (Zepbound; Mounjaro for type 2 diabetes) · Liraglutide (Saxenda; Victoza for type 2 diabetes)
- Formats reviewed
- Injection · Oral medicine
- Funding routes
- Private pay · Insurance support
- Service features
- Clinician support · Switching pathway · Home delivery
- Access check
- Confirm current state access
- Evidence status
- Primary sources reviewed
- Research depth
- 2 cited sources · 4 medicine rows · 4 open checks
Recurring cost breakdown
- $39 first program month and $149/month thereafter were advertised.
- Medication cost is separate and depends on cash pricing or insurance.
- Clinician consults, coaching, and essential lab work are included when the patient has not completed qualifying labs in the prior 12 months.
- No-insurance cash alternatives may materially increase the total.
- Medicine + dose
- Membership or consultation
- Delivery + supplies
- Labs + follow-up
- Renewal after offers
Medication and formulation matrix
| Medication | Form | Regulatory / program path | Published price view |
|---|---|---|---|
| Wegovy / Zepbound | Pill, vial, KwikPen or pen as offered | FDA-approved brand | Separate; cash or insurance |
| Foundayo | Daily pill | FDA-approved brand | Separate; verify current price |
| Ozempic / Saxenda | Injection | FDA-approved; indications differ | Separate; eligibility and coverage dependent |
| Metformin + bupropion + topiramate | Oral combination pathway | Clinician-selected; uses and approvals vary | Verify plan-specific total |
Important: “Compounded” means the product is not FDA approved. A brand approved for one condition is not automatically approved for another. The treating clinician determines whether any prescription is appropriate.
State-by-state availability
- Multi-state virtual access is advertised; confirm clinician and product eligibility during intake.
- Government-plan users face specific eligibility restrictions disclosed by the program.
Clinician access and follow-up cadence
- Clinician consultation and ongoing monitoring are included.
- Coaching and care-team support are advertised; exact follow-up timing depends on the treatment plan.
Pharmacy and fulfillment
- The fulfillment route varies by brand, cash, and insurance pathway.
- Confirm retail versus delivery pharmacy and inventory before transferring a prescription.
Insurance and prior authorization
- LifeMD assists with prior authorization and medication coverage.
- If coverage is denied, the patient may choose cash access or cancel; incurred membership fees are generally not refunded solely because of denial.
Cancellation, refund, and commitment
- The program advertises cancel-anytime membership.
- Cancel before the next billing cutoff; medication orders, laboratory services, and already-incurred program fees can have separate refund treatment.
Labs, monitoring, and dose management
- Essential lab work is included when acceptable results were not completed in the prior 12 months.
- Ongoing monitoring is care-plan dependent; ask which panel and repeat cadence apply.
Maintenance and switching
- The broader clinical model can support longer-term management.
- A switch can trigger a new insurance authorization and new labs; preserve supply until acceptance and timing are confirmed.
Program snapshot
Membership plus medication
Profiled support: Ongoing clinician access.
Cash pay · Insurance help
The medication path may depend on coverage or direct-pay brand access.
Verify before purchase
Confirm the chosen product’s dispensing pharmacy and whether LifeMD or a manufacturer channel handles fulfillment.
What the advertised program may include
- Clinician-led program
- Ongoing virtual care
- Medication access when prescribed
- Care-team communication
Useful comparison signals
Based on the provider’s published program structure, this profile is tagged for the following searches. These are filters, not endorsements or clinical recommendations.
- Starting care and comparing first-provider requirements
- Switching providers or continuing an established treatment
- Ongoing clinician access
Open evidence gaps
These are material details we could not confirm precisely enough from the cited public pages. They are the highest-priority questions to resolve directly.
- Named fulfillment pharmacy by product
- Guaranteed insurance turnaround
- One published follow-up schedule for all pathways
- Exact cash medication total before intake
Questions to ask before paying
- What is the ordinary recurring total after any introductory period?
- Does that total include clinician care, medication, supplies, labs, and shipping?
- Which clinician group and dispensing pharmacy will be responsible for my care?
- What happens to billing if I am not prescribed the advertised treatment?
- What records and timing do you require if I am switching from another provider?
Source ledger
Every entry below is a provider-controlled or official public source. A source link documents what was published; it does not independently validate performance, regulatory compliance, safety, or outcomes.
Program price, medications, labs, coaching, insurance and cancellation claims
Billing, service and cancellation framework